255 related articles for article (PubMed ID: 32365405)
1. Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non-alcoholic steatohepatitis.
Kobayashi T; Kanno K; Nguyen PT; Sugiyama A; Kawahara A; Otani Y; Kishikawa N; Ito M; Tazuma S
J Gastroenterol Hepatol; 2020 Dec; 35(12):2140-2150. PubMed ID: 32365405
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of antisense oligonucleotide therapy targeting Hsd17b13 in a fibrosis mice model.
Ma Y; Cai H; Smith J; Chu CH; Mercer SE; Boehm S; Mcdonald I; Zinker B; Cheng D
J Lipid Res; 2024 Mar; 65(3):100514. PubMed ID: 38309418
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
4. The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse.
Takano K; Kaneda M; Aoki Y; Fujita N; Chiba S; Michihara S; Han LK; Takahashi R
J Nat Med; 2024 Jun; 78(3):514-524. PubMed ID: 38498120
[TBL] [Abstract][Full Text] [Related]
5. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
Liu L; Liu C; Zhao M; Zhang Q; Lu Y; Liu P; Yang H; Yang J; Chen X; Yao Y
PLoS One; 2020; 15(12):e0243911. PubMed ID: 33326461
[TBL] [Abstract][Full Text] [Related]
6. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
[TBL] [Abstract][Full Text] [Related]
7. Depletion of hepatic stellate cells inhibits hepatic steatosis in mice.
Kawahara A; Kanno K; Yonezawa S; Otani Y; Kobayashi T; Tazuma S; Ito M
J Gastroenterol Hepatol; 2022 Oct; 37(10):1946-1954. PubMed ID: 35933582
[TBL] [Abstract][Full Text] [Related]
8. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
9. Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling.
Li SW; Takahara T; Que W; Fujino M; Guo WZ; Hirano SI; Ye LP; Li XK
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G450-G463. PubMed ID: 33439102
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte-specific loss of LAP2α protects against diet-induced hepatic steatosis, steatohepatitis, and fibrosis in male mice.
Upadhyay KK; Choi EK; Foisner R; Omary MB; Brady GF
Am J Physiol Gastrointest Liver Physiol; 2023 Aug; 325(2):G184-G195. PubMed ID: 37366543
[TBL] [Abstract][Full Text] [Related]
11. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL
Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798
[TBL] [Abstract][Full Text] [Related]
12. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
[TBL] [Abstract][Full Text] [Related]
13. Deletion of TRPC3 or TRPC6 Fails to Attenuate the Formation of Inflammation and Fibrosis in Non-alcoholic Steatohepatitis.
Nishiyama K; Toyama C; Kato Y; Tanaka T; Nishimura A; Nagata R; Mori Y; Nishida M
Biol Pharm Bull; 2021; 44(3):431-436. PubMed ID: 33642551
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis.
Win S; Min RWM; Zhang J; Kanel G; Wanken B; Chen Y; Li M; Wang Y; Suzuki A; Aung FWM; Murray SF; Aghajan M; Than TA; Kaplowitz N
Hepatology; 2021 Dec; 74(6):3127-3145. PubMed ID: 34331779
[TBL] [Abstract][Full Text] [Related]
15. Hepatic Krüppel-like factor 14 regulates lipid metabolism in nonalcoholic steatohepatitis mice.
Chen X; Shi W; Xie Y; Wang Y; Yao Q; Ke H; Xu X; Liu H; Liu P; Zhou X
FASEB J; 2023 Aug; 37(8):e23070. PubMed ID: 37389939
[TBL] [Abstract][Full Text] [Related]
16. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis.
Hsieh YC; Wu PS; Lin YT; Huang YH; Hou MC; Lee KC; Lin HC
FASEB J; 2022 Oct; 36(10):e22526. PubMed ID: 36063123
[TBL] [Abstract][Full Text] [Related]
17. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
[TBL] [Abstract][Full Text] [Related]
18. Blocking integrin α
Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
[TBL] [Abstract][Full Text] [Related]
19. Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
Du M; Wang X; Yuan L; Liu B; Mao X; Huang D; Yang L; Huang K; Zhang F; Wang Y; Luo X; Wang C; Peng J; Liang M; Huang D; Huang K
J Hepatol; 2020 Dec; 73(6):1333-1346. PubMed ID: 32717288
[TBL] [Abstract][Full Text] [Related]
20. The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
Bae CR; Zhang H; Kwon YG
PLoS One; 2020; 15(12):e0243497. PubMed ID: 33275637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
